Boehringer Ingelheim And IBM Collaborate To Advance Generative AI And Foundation Models For Therapeutic Antibody Development
Ingelheim, Germany and Armonk N.Y., November 28, 2023 – Today, Boehringer Ingelheim and IBM (NYSE:IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the…
Share